Related Experiment Videos
Cancer therapy: new concepts on active immunization
1Department of Tumor Progression and Immune Defense, German Cancer Research Center, Heidelberg. m.zoeller@dkfz-heidelberg.de
Abstract:
There is increasing evidence that tumors express putative target molecules for a therapeutic immune reaction. Yet, tumor cells lack the prerequisites for appropriate antigen presentation and--hence--the immune system does not respond. This difficulty can probably be circumvented when tumor antigens are processed by conventional antigen presenting cells. Thus, the identification of immunogenic tumor-associated antigens may allow new modes of vaccination with the hope of adding a fourth and hopefully powerful weapon to surgery, radiation and chemotherapy in the fight against cancer.
Insights
Identifying immunogenic tumor antigens could enable new cancer vaccines. This approach bypasses tumor cells' poor antigen presentation, potentially activating a robust immune response to fight cancer.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Tumors express molecules targeted by immunotherapy.
- Tumor cells often fail at antigen presentation, hindering immune response.
- Conventional antigen-presenting cells can process tumor antigens.
Purpose of the Study:
- To explore the potential of targeting tumor antigens for cancer vaccination.
- To overcome the limitations of tumor cell antigen presentation.
- To develop novel immunotherapeutic strategies against cancer.
Main Methods:
- Identification of immunogenic tumor-associated antigens.
- Investigating antigen processing by antigen-presenting cells.
Main Results:
- Established the principle of using antigen-presenting cells for tumor antigen processing.
- Highlighted the potential for developing cancer vaccines based on tumor antigens.
Conclusions:
- Identifying immunogenic tumor antigens is crucial for effective cancer vaccines.
- This strategy offers a promising new avenue for cancer treatment.
- Cancer vaccines could become a significant addition to existing cancer therapies.